The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Targeted drug delivery to tumors: Myths, reality and possibility
Open accessAbstract
The ultimate goal of drug delivery research is to help patients by developing clinically useful formulations. During the last several decades controlled drug delivery technology has advanced significantly, leading to the development of various clinical formulations improving patient compliance and convenience [1]. Current technologies allow delivery of drugs at desired release kinetics for extended periods of time ranging from days to years. Oral and transdermal drug delivery systems routinely deliver drugs for 24 h, substantially improving drug efficacy and minimizing side effects. Implantable systems can locally deliver drugs for months, even years. While significant advances have been made, there are still areas where substantial improvements need to be made to reach the next level of clinical relevance. One such area is targeted drug delivery to solid tumors. The clinically significant impact of targeted drug delivery lies in the ability to specifically target a drug or drug carrier to minimize drug-originated systemic toxic effects. Successful translation (from bench to bedside) of potential cancer and gene therapies, particularly small interfering RNA (siRNA) delivery, will largely depend on targeted drug delivery strategies. Overcoming the many challenges of identifying a successful targeted drug delivery strategy requires an understanding of events involving transport of drug or drug carrier to a target site after intravenous (i.v.) administration as well as issues relevant for specific target diseases and the body’s response toward a drug delivery system. The current lack of clear recognition of problems facing the drug delivery field can be anticipated to result in only marginal advances in targeted drug delivery technologies in the coming years. The current unmet needs and challenges in this area were summarized by Professor Alexander T. Florence who is one of the few who raised awareness on the exaggerated claims of the nanoparticle-based drug targeting [2,3]. They need to be better appreciated and understood for achieving greater success in drug targeting to tumors. Thus, it would be profitable to address a variety of issues and factors that could affect the development of improved targeted drug delivery systems. Many terms have been used to describe nano-sized drug delivery systems, and here the term “nanoparticle” is used to represent a spectrum of systems, including nanocarrier, nanovehicle, nanosystem, nanostructure, and other terms used in the literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Visvader, J. E. (2011) · Nature · doi:10.1038/nature09781 · Cited by 1,449
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.-H., Diebel, M. E., Monville, F., Dutcher, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2741 · Cited by 1,173
Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.08.017 · Cited by 1,162
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Biological Diversity in Metastatic Neoplasms: Origins and Implications
Fidler, I. J., & Hart, I. R. (1982) · Science · doi:10.1126/science.7112116 · Cited by 928
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., & Jain, R. K. (1994) · PubMed · Cited by 908
Silica Particles: A Novel Drug‐Delivery System
Barbé, C., Bartlett, J., Kong, L., Finnie, K., Lin, H. Q., Larkin, M., Calleja, S., Bush, A., & Calleja, G. (2004) · Advanced Materials · doi:10.1002/adma.200400771 · Cited by 859
Yamaoka, T., Tabata, Y., & Ikada, Y. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830432 · Cited by 748
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
Torchilin, V. P. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00166-4 · Cited by 680
Iliopoulos, D., Hirsch, H. A., Wang, G., & Struhl, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018898108 · Cited by 643
Targeted therapies: a new generation of cancer treatments.
Gerber, D. E. (2008) · PubMed · Cited by 638
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Nam, H. Y., Kwon, S. M., Chung, H., Lee, S.-Y., Kwon, S.-H., Jeon, H., Kim, Y., Park, J. H., Kim, J., Her, S., et al. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.01.018 · Cited by 564
Litzinger, D. C., Buiting, A. M. J., van Rooijen, N., & Huang, L. (1994) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(94)90038-8 · Cited by 546
PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats
Li, Y.-P., Pei, Y.-Y., Zhang, X.-Y., Gu, Z.-H., Zhou, Z.-H., Yuan, W.-F., Zhou, J.-J., Zhu, J.-H., & Gao, X.-J. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00218-8 · Cited by 540
Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., & Jain, R. K. (1994) · PubMed · Cited by 463
Zensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
Chen, H., Kim, S., Li, L., Wang, S., Park, K., & Cheng, J.-X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707046105 · Cited by 394
Self-citationJain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Lee, H., Fonge, H., Hoang, B., Reilly, R. M., & Allen, C. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100038h · Cited by 349
Does a targeting ligand influence nanoparticle tumor localization or uptake?
Pirollo, K. F., & Chang, E. H. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.06.007 · Cited by 347
Konno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Morinaga, T., Mochinaga, M., Hiraoka, T., & Yokoyama, I. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90028-7 · Cited by 342
Mikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Chen, H., Kim, S., He, W., Wang, H., Low, P. S., Park, K., & Cheng, J.-X. (2008) · Langmuir · doi:10.1021/la703570m · Cited by 311
Self-citationTumor heterogeneity: biological implications and therapeutic consequences
Heppner, G. H., & Miller, B. E. (1983) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046903 · Cited by 307
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Endomitotic Reduplication Mechanisms in Ascites Tumors of the Mouse 2
(1953) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/14.1.1 · Cited by 279
Choi, K. Y., Min, K. H., Na, J. H., Choi, K., Kim, K., Park, J. H., Kwon, I. C., & Jeong, S. Y. (2009) · Journal of Materials Chemistry · doi:10.1039/b900456d · Cited by 272
Nanosystem drug targeting: Facing up to complex realities
Ruenraroengsak, P., Cook, J. M., & Florence, A. T. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.032 · Cited by 265
Burt, H. M., Zhang, X., Toleikis, P., Embree, L., & Hunter, W. L. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00067-3 · Cited by 254
Drug targeting and tumor heterogeneity
Bae, Y. H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.074 · Cited by 233
Self-citationMaeda, H., Ueda, M., Morinaga, T., & Matsumoto, T. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00382a012 · Cited by 225
Hwang-Verslues, W. W., Kuo, W.-H., Chang, P.-H., Pan, C.-C., Wang, H.-H., Tsai, S.-T., Jeng, Y.-M., Shew, J.-Y., Kung, J. T., Chen, C.-H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008377 · Cited by 223
Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin
Hong, M., Zhu, S., Jiang, Y., Tang, G., & Pei, Y. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.09.005 · Cited by 218
Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle–cell interactions
Savić, R., Eisenberg, A., & Maysinger, D. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600874538 · Cited by 218
Lee, S. C., Huh, K. M., Lee, J., Cho, Y. W., Galinsky, R. E., & Park, K. (2007) · Biomacromolecules · doi:10.1021/bm060307b · Cited by 206
Self-citationIs Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?
Adams, J. M., & Strasser, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6334 · Cited by 204
Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H., Kubista, E., Kwasny, W., Kandioler-Eckersberger, D., Gnant, M., et al. (2001) · PubMed · Cited by 197
Savić, R., Azzam, T., Eisenberg, A., & Maysinger, D. (2006) · Langmuir · doi:10.1021/la0531998 · Cited by 191
Polymer therapeutics: Clinical applications and challenges for development
Vicent, M. J., Ringsdorf, H., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.08.001 · Cited by 183
Leamon, C. P., Cooper, S. R., & Hardee, G. E. (2003) · Bioconjugate Chemistry · doi:10.1021/bc020089t · Cited by 180
Jani, P. U., McCarthy, D. E., & Florence, A. T. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90202-d · Cited by 172
Mimeault, M., Hauke, R., & Batra, S. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100296 · Cited by 168
Milosevic, M., Fyles, A., Hedley, D., & Hill, R. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.006 · Cited by 163
Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments
Béduneau, A., Saulnier, P., Hindré, F., Clavreul, A., Leroux, J.-C., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.014 · Cited by 161
Combined cancer therapy by micellar-encapsulated drug and ultrasound
Rapoport, N. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.048 · Cited by 159
Transendothelial Transport: The Vesicle Controversy
Rippe, B., Rosengren, B.-I., Carlsson, O., & Venturoli, D. (2002) · Journal of Vascular Research · doi:10.1159/000064521 · Cited by 159
Yamaoka, T., Tabata, Y., & Ikada, Y. (1995) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1995.tb05835.x · Cited by 157
Gao, Z.-G., Tian, L., Hu, J., Park, I.-S., & Bae, Y. H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.021 · Cited by 144
Self-citationMills, J. K., & Needham, D. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.11.1499 · Cited by 112
Damia, G. L. M., & D’Incalci, M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.08.008 · Cited by 84
Relevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates
Canal, F., Vicent, M. J., Pasut, G., & Schiavon, O. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.027 · Cited by 82
Implications of tumor progression on clinical oncology
Welch, D. R., & Tomasovic, S. P. (1985) · Clinical & Experimental Metastasis · doi:10.1007/bf01786761 · Cited by 74
To PEGylate or not to PEGylate, that is not the question
Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.025 · Cited by 70
Self-citationDynamics of magnetic lipoplexes studied by single particle tracking in living cells
Sauer, A., de Bruin, K. G., Ruthardt, N., Mykhaylyk, O. M., Plank, C., & Bräuchle, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.003 · Cited by 66
Lin, C., Liu, T., Chen, C.-Y., Huang, Y., Huang, W., Sun, C., Chang, F., & Lin, W.-L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.033 · Cited by 61
Duguet, É. (2008) · Macromolecular Chemistry and Physics · doi:10.1002/macp.200800184 · Cited by 59
Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo
Richardson, S. C. W., Pattrick, N. G., Lavignac, N., Ferruti, P., & Duncan, R. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.025 · Cited by 56
Hepatic circulation: Potential for therapeutic intervention
Ballet, F. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90091-f · Cited by 56
Räägel, H., Säälik, P., Hansen, M., Langel, Ü., & Pooga, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.028 · Cited by 55
Intratumor immunologic heterogeneity
Miller, F. R. (1982) · Cancer and Metastasis Reviews · doi:10.1007/bf00124215 · Cited by 50
Monitoring intracellular degradation of exogenous DNA using diffusion properties
Sasaki, A., & Kinjo, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.013 · Cited by 48
Targeted Toxins in Brain Tumor Therapy
Li, Y. M., & Hall, W. A. (2010) · Toxins · doi:10.3390/toxins2112645 · Cited by 45
Pharmaceutical nanotechnology: More than size
Florence, A. T. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.009 · Cited by 33
LYMPH AND THE LYMPHATIC SYSTEM
Rosenberg, S. A. (1969) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196908000-00017 · Cited by 31
Polymeric Nanoparticles and Nanopore Membranes for Controlled Drug and Gene Delivery
Guan, J., He, H., Yu, B., & Lee, L. J. (2007) · Biomedical Nanostructures · doi:10.1002/9780470185834.ch6 · Cited by 11 · cited 1×
“Since long-term circulation in blood is important for targeted drug delivery and sustained release [38], studies using nanoparticles with narrow size distribution will be critical for optimizing desired biodistribution parameters.”
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Metadata
- Authors
- Bae, Y. H., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 153
- Issue
- 3
- Pages
- 198-205
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2070003597
- Cited by
- 1,935
- References
- 81
- FWCI
- 31.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.